Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Colorectal Neoplasms

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 41 articles: HTML format

Single Articles

May 2025
1. MOMEN-ROKNABADI A, Karimzadeh M, Chen NC, Cavazos TB, et al
   Detection of Early-Stage Colorectal Cancer Using Cell-Free oncRNA Biomarkers and Artificial Intelligence.
   Clin Cancer Res. 2025 May 14. doi: 10.1158/1078-0432.CCR-25-0449.
   PubMed     Abstract available
   
   
   
2. APPLEYARD JW, Williams CJM, Manca P, Pietrantonio F, et al
   Targeting the MAP kinase pathway in colorectal cancer: A journey in personalized medicine.
   Clin Cancer Res. 2025 May 1. doi: 10.1158/1078-0432.CCR-25-0107.
   PubMed     Abstract available
   
   
   
3. WANKHEDE D, Halama N, Kloor M, Edelmann D, et al
   Prognostic Value of CD8+ T Cells at the Invasive Margin Is Comparable to the Immune Score in Nonmetastatic Colorectal Cancer: A Prospective Multicentric Cohort Study.
   Clin Cancer Res. 2025;31:1711-1718.
   PubMed     Abstract available
   
   
   
4. MORRIS VK, Liu S, Lin K, Zhu H, et al
   Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal.
   Clin Cancer Res. 2025;31:1657-1666.
   PubMed     Abstract available
   
   
   April 2025
5. ONG JC, Zhao JJ, Liu Y, Srivastava S, et al
   Spatial heterogeneity, stromal phenotypes, and therapeutic vulnerabilities in colorectal cancer peritoneal metastasis.
   Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-24-3780.
   PubMed     Abstract available
   
   
   
6. SIRKIA O, Karjalainen H, Elomaa H, Vayrynen SA, et al
   Multimarker assessment of B cell and plasma cell subsets and their prognostic role in the colorectal cancer microenvironment.
   Clin Cancer Res. 2025 Apr 8. doi: 10.1158/1078-0432.CCR-24-4083.
   PubMed     Abstract available
   
   
   
7. CHAUDHARY N, La Ferlita A, Choudhary BS, Jog E, et al
   Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas.
   Clin Cancer Res. 2025;31:1359-1373.
   PubMed     Abstract available
   
   
   March 2025
8. LI C, Noonan AM, Hays J, Roychowdhury S, et al
   Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase 1 Clinical Trial.
   Clin Cancer Res. 2025 Mar 21. doi: 10.1158/1078-0432.CCR-24-3964.
   PubMed     Abstract available
   
   
   
9. GULLER U, Hayoz S, Horber D, Jochum W, et al
   Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients: The SAKK 41/13 - Prospective Randomized Placebo-Controlled Double-Blind Trial.
   Clin Cancer Res. 2025 Mar 11. doi: 10.1158/1078-0432.CCR-24-4048.
   PubMed     Abstract available
   
   
   
10. JAZIEH K, Tsai J, Solomon S, Zhu M, et al
    Identification of Candidate Alterations Mediating KRASG12C Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers.
    Clin Cancer Res. 2025;31:899-906.
    PubMed     Abstract available
    
    
    February 2025
11. HENRIKSEN TV, Demuth C, Frydendahl A, Nors J, et al
    Timing of circulating tumor DNA analysis aimed at guiding adjuvant treatment in colorectal cancer.
    Clin Cancer Res. 2025 Feb 20. doi: 10.1158/1078-0432.CCR-24-3200.
    PubMed     Abstract available
    
    
    
12. SABERZADEH-ARDESTANI B, Liu Z, Stein MI, Sherman WA, et al
    Spatially resolved, multi-region proteomics for prediction of immunotherapy outcome in deficient mismatch repair metastatic colorectal cancer.
    Clin Cancer Res. 2025 Feb 19. doi: 10.1158/1078-0432.CCR-24-0853.
    PubMed     Abstract available
    
    
    
13. SCHOENFELD JD, Azad NS, Gross J, Chen L, et al
    Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D.
    Clin Cancer Res. 2025;31:667-677.
    PubMed     Abstract available
    
    
    
14. LIU C, Zou H, Ruan Y, Fang L, et al
    Multiomics Reveals the Immunologic Features and the Immune Checkpoint Blockade Potential of Colorectal Medullary Carcinoma.
    Clin Cancer Res. 2025;31:773-786.
    PubMed     Abstract available
    
    
    
15. CIOMBOR KK, Bae SW, Whisenant JG, Ayers GD, et al
    Results of the phase I/II study and preliminary B cell gene signature of combined inhibition of glutamine metabolism and EGFR in colorectal cancer.
    Clin Cancer Res. 2025 Feb 10. doi: 10.1158/1078-0432.CCR-24-3133.
    PubMed     Abstract available
    
    
    January 2025
16. XU C, Mannucci A, Esposito F, Oliveres H, et al
    An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study.
    Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-1934.
    PubMed     Abstract available
    
    
    
17. WEST EJ, Sadoun A, Bendjama K, Erbs P, et al
    A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancer.
    Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-2498.
    PubMed     Abstract available
    
    
    December 2024
18. GHIDINI M, Hahne JC, Senti C, Heide T, et al
    Circulating tumor DNA dynamics and clinical outcome in metastatic colorectal cancer patients undergoing front-line chemotherapy.
    Clin Cancer Res. 2024 Dec 17. doi: 10.1158/1078-0432.CCR-24-0924.
    PubMed     Abstract available
    
    
    
19. PIETRANTONIO F, Morano F, Niger M, Ghelardi F, et al
    The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite Stable Metastatic Colorectal Cancer: A Phase 1b/2a Trial.
    Clin Cancer Res. 2024 Dec 2. doi: 10.1158/1078-0432.CCR-24-2611.
    PubMed     Abstract available
    
    
    November 2024
20. NAKAMURA Y, Kaneva K, Lo C, Neems D, et al
    A tumor-naive ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan.
    Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-2396.
    PubMed     Abstract available
    
    
    October 2024
21. MACFARLAND SP, Becktell K, Schneider KW, Kuiper RP, et al
    Pediatric Cancer Screening in Hereditary Gastrointestinal Cancer Risk Syndromes: An Update from the AACR Childhood Cancer Predisposition Working Group.
    Clin Cancer Res. 2024;30:4566-4571.
    PubMed     Abstract available
    
    
    
22. ANDERSSON A, Escriva Conde M, Surova O, Vermeulen P, et al
    Spatial Transcriptome Mapping of the Desmoplastic Growth Pattern of Colorectal Liver Metastases by In Situ Sequencing Reveals a Biologically Relevant Zonation of the Desmoplastic Rim.
    Clin Cancer Res. 2024;30:4517-4529.
    PubMed     Abstract available
    
    
    September 2024
23. LEE HM, Saw AK, Morris VK, Napolitano S, et al
    Epigenome reprogramming through H3K27 and H3K4 trimethylation as a resistance mechanism to DNA methylation inhibition in BRAFV600E-mutated colorectal cancer.
    Clin Cancer Res. 2024 Sep 13. doi: 10.1158/1078-0432.CCR-24-1166.
    PubMed     Abstract available
    
    
    August 2024
24. IIDA N, Imai M, Okamoto W, Kato T, et al
    Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.
    Clin Cancer Res. 2024 Aug 20:OF1-OF12. doi: 10.1158/1078-0432.CCR-24-1023.
    PubMed     Abstract available
    
    
    
25. DAS A, MacFarland SP, Meade J, Hansford JR, et al
    Clinical Updates and Surveillance Recommendations for DNA Replication Repair Deficiency Syndromes in Children and Young Adults.
    Clin Cancer Res. 2024;30:3378-3387.
    PubMed     Abstract available
    
    
    
26. NAKAMURA Y, Tsukada Y, Matsuhashi N, Murano T, et al
    Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay.
    Clin Cancer Res. 2024 Aug 7. doi: 10.1158/1078-0432.CCR-24-1651.
    PubMed     Abstract available
    
    
    
27. CHANG W, Zhang Z, Jia B, Ding K, et al
    A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study.
    Clin Cancer Res. 2024;30:3337-3348.
    PubMed     Abstract available
    
    
    June 2024
28. JOHANSEN AM, Forsythe SD, McGrath CT, Barker G, et al
    TGFbeta in pancreas and colorectal cancer: opportunities to overcome therapeutic resistance.
    Clin Cancer Res. 2024 Jun 25. doi: 10.1158/1078-0432.CCR-24-0468.
    PubMed     Abstract available
    
    
    
29. LENTZ RW, Friedrich TJ, Blatchford PJ, Jordan KR, et al
    A phase II study of potentiation of pembrolizumab with binimetinib and bevacizumab in refractory microsatellite stable colorectal cancer.
    Clin Cancer Res. 2024 Jun 13. doi: 10.1158/1078-0432.CCR-24-0090.
    PubMed     Abstract available
    
    
    
30. SLATER S, Bryant A, Aresu M, Begum R, et al
    Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC Part B study.
    Clin Cancer Res. 2024 Jun 12. doi: 10.1158/1078-0432.CCR-24-0226.
    PubMed     Abstract available
    
    
    May 2024
31. FUSCO MJ, Casak SJ, Mushti SL, Cheng J, et al
    FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
    Clin Cancer Res. 2024 May 29. doi: 10.1158/1078-0432.CCR-24-0281.
    PubMed     Abstract available
    
    
    
32. VOISIN A, Terret C, Schiffler C, Bidaux AS, et al
    Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial.
    Clin Cancer Res. 2024;30:2111-2120.
    PubMed     Abstract available
    
    
    
33. LOREE JM, Titmuss E, Topham JT, Kennecke HF, et al
    Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial.
    Clin Cancer Res. 2024 May 10. doi: 10.1158/1078-0432.CCR-24-0268.
    PubMed     Abstract available
    
    
    
34. PARIKH AR, Chee BH, Tsai J, Rich TA, et al
    Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    Clin Cancer Res. 2024 May 2. doi: 10.1158/1078-0432.CCR-23-3660.
    PubMed     Abstract available
    
    
    
35. WU C, Pai RK, Kosiorek H, Banerjee I, et al
    Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC.
    Clin Cancer Res. 2024;30:1811-1821.
    PubMed     Abstract available
    
    
    
36. KHUSHMAN MM, Toboni MD, Xiu J, Manne U, et al
    Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations.
    Clin Cancer Res. 2024;30:1906-1915.
    PubMed     Abstract available
    
    
    April 2024
37. WILBUR HC, Le DT, Agarwal P
    Immunotherapy of MSI Cancer: Facts and Hopes.
    Clin Cancer Res. 2024;30:1438-1447.
    PubMed     Abstract available
    
    
    
38. MOUILLET-RICHARD S, Cazelles A, Sroussi M, Gallois C, et al
    Clinical challenges of consensus molecular subtype CMS4 colon cancer in the era of precision medicine.
    Clin Cancer Res. 2024 Apr 2. doi: 10.1158/1078-0432.CCR-23-3964.
    PubMed     Abstract available
    
    
    March 2024
39. HARROLD E, Keane F, Walch H, Chou JF, et al
    Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer.
    Clin Cancer Res. 2024 Mar 19. doi: 10.1158/1078-0432.CCR-23-4005.
    PubMed     Abstract available
    
    
    
40. MALVIYA G, Lannagan TRM, Johnson E, Mackintosh A, et al
    Noninvasive Stratification of Colon Cancer by Multiplex PET Imaging.
    Clin Cancer Res. 2024 Mar 17:OF1-OF12. doi: 10.1158/1078-0432.CCR-23-1063.
    PubMed     Abstract available
    
    
    
41. STEBBING J, Bullock AJ
    Polo-like kinase 1 inhibition in KRAS-mutated metastatic colorectal cancer.
    Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-24-0251.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.